These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21663507)

  • 41. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Binkley MS; Flerlage JE; Savage KJ; Akhtar S; Steiner R; Zhang XY; Dickinson M; Prica A; Major A; Hendrickson PG; Hopkins D; Ng A; Casulo C; Baron J; Roberts KB; Al Kendi J; Balogh A; Ricardi U; Torka P; Specht L; De Silva R; Pickard K; Blazin LJ; Henry M; Smith CM; Halperin D; Brady J; Brennan B; Senchenko MA; Reeves M; Hoppe BS; Terezakis S; Talaulikar D; Picardi M; Kirova Y; Fergusson P; Hawkes EA; Lee D; Doo NW; Barraclough A; Cheah CY; Ku M; Hamad N; Mutsando H; Gilbertson M; Marconi T; Viiala N; Maurer MJ; Eichenauer DA; Hoppe RT;
    J Clin Oncol; 2024 Jul; 42(19):2271-2280. PubMed ID: 38531001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
    Advani RH; Hoppe RT
    Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
    Feugier P; Labouyrie E; Djeridane M; Jenabian A; Dubruille V; Berthou C; Ghandour C; Desablens B; Chaït Y; Casassus P; Delwail V; Ifrah N; Le Mevel A; Lamy T; Brière J; Colonna P; Andrieu JM
    Blood; 2004 Nov; 104(9):2675-81. PubMed ID: 15231567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity.
    de Jong D; Bosq J; MacLennan KA; Diebold J; Audouin J; Chasle J; Mandard AM; Marnay J; Henry-Amar M; ;
    Ann Oncol; 2006 Jan; 17(1):141-5. PubMed ID: 16284059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
    Unal A; Sari I; Deniz K; Ozkan M; Kontas O; Eser B; Cetin M
    Leuk Lymphoma; 2005 Nov; 46(11):1613-7. PubMed ID: 16236615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
    Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nodular lymphocyte-predominant Hodgkin lymphoma: cytopathologic correlates on fine-needle aspiration.
    Subhawong AP; Ali SZ; Tatsas AD
    Cancer Cytopathol; 2012 Aug; 120(4):254-60. PubMed ID: 22367911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nodular lymphocyte predominant Hodgkin lymphoma.
    Lee AI; LaCasce AS
    Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group.
    Shankar AG; Kirkwood AA; Depani S; Bianchi E; Hayward J; Ramsay AD; Hall GW
    Br J Haematol; 2016 May; 173(3):421-31. PubMed ID: 26996288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular).
    Hansmann ML; Zwingers T; Böske A; Löffler H; Lennert K
    J Cancer Res Clin Oncol; 1984; 108(3):321-30. PubMed ID: 6511805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
    Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
    J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.
    Hartmann S; Schuhmacher B; Rausch T; Fuller L; Döring C; Weniger M; Lollies A; Weiser C; Thurner L; Rengstl B; Brunnberg U; Vornanen M; Pfreundschuh M; Benes V; Küppers R; Newrzela S; Hansmann ML
    Leukemia; 2016 Apr; 30(4):844-53. PubMed ID: 26658840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
    J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.
    Kumar A; Burger IA; Zhang Z; Drill EN; Migliacci JC; Ng A; LaCasce A; Wall D; Witzig TE; Ristow K; Yahalom J; Moskowitz CH; Zelenetz AD
    Haematologica; 2016 Oct; 101(10):1237-1243. PubMed ID: 27390360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nodular lymphocyte predominant Hodgkin lymphoma: Experience of Polish Pediatric Leukemia/Lymphoma Study Group.
    Klekawka T; Balwierz W; Brozyna A; Chaber R; Dadela-Urbanek A; Koltan A; Kwasnicka J; Mitura-Lesiuk M; Muszynska-Roslan K; Przybyszewski B; Ruranska I; Smalisz K; Mizia-Malarz A; Stachowicz-Stencel T; Stolarska M; Wziatek A; Zielezinska K; Skoczen S
    Pediatr Hematol Oncol; 2021 Oct; 38(7):609-619. PubMed ID: 33734010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Savage KJ; Mottok A; Fanale M
    Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
    Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?
    Barber NA; Loberiza FR; Perry AM; Bast M; Holdeman KP; Esfahane AB; Weisenburger DD; Vose J; Bierman P; Armitage JO; Bociek RG
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):392-7. PubMed ID: 23773450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.